Trial Profile
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bictegravir (Primary) ; Emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 13 Mar 2019 Status changed from active, no longer recruiting to completed.
- 08 Oct 2017 Results presented at the IDWeek 2017
- 30 Jun 2017 Planned End Date changed from 1 Feb 2018 to 1 Jan 2019.